PBI-4050 sodium salt (Setogepram (sodium salt)) (Synonyms: Setogepram sodium; PBI-4050 sodium) |
カタログ番号GC31698 |
フェザゲプラス (セトゲプラム) ナトリウムは、GPR40 の経口活性アゴニストとして作用し、GPR84 のアンタゴニストまたは逆アゴニストとして作用します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1254472-97-3
Sample solution is provided at 25 µL, 10mM.
PBI-4050 acts as an agonist for GPR40 and as an antagonist or inverse agonist for GPR84.
PBI-4050, a synthetic analogue of a medium-chain length fatty acid, binds to FFA receptor 1 (FFAR1/GPR40) and GPR84. To determine the potential role of PBI-4050 on diabetic kidney disease, The accelerated model of type 2 diabetic nephropathy, eNOS-/- db/db mice are utilized. Mice are treated with either vehicle or PBI-4050 (100 mg/kg) by daily gavage from 8-20 weeks of age. eNOS-/- db/db mice are moderately hypertensive, and PBI-4050 has no effect on blood pressure. Furthermore, compared with vehicle-treated mice, which exhibit a decrease in glomerular filtration rate (GFR) from 8-20 weeks, PBI-4050 preserves GFR. Podocyte number per glomerulus section markedly decreases from 8-20 weeks of age in vehicle-treated mice, while PBI-4050 treatment significantly slows this loss[1].
[1]. Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365.
Average Rating: 5
(Based on Reviews and 23 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *